ALXN News and Press, Alexion Pharmaceuticals Inc. From 12/14/20

The consolidation of biopharma customers is 'a risk to CROs’ as it can lead to downsizing of R&D budgets and outsourcing, Bank of America says in a note evaluating the impact on IQVIA Holdings (IQV) from the proposed merger between Alexion (ALXN) and AstraZeneca (AZN).Identifying I...

AnPac Bio-Medical Science (ANPC) +99% as company makes significant progress in detecting pre-cancer diseases.Arvinas (ARVN) +74% after releasing interim clinical data of PROTAC® protein degraders.Veru (VERU) +57% on positive phase 2 clinical trial results for Enobosarm.Syn...

Alexion (ALXN) pops +31.2% in pre-market trading after AstraZeneca (AZN) announced over the weekend, it was acquiring the rare-disease specialist in a deal worth $39B.AstraZeneca’s US-listed shares have sunk -5.7% in pre-market, while in the U.K, the company’s London-l...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Vaccine rolloutLess than two days after the FDA granted emergency authorization for Pfizer (NYSE:PFE) and BioNTech's (NASDAQ:BNTX) COVID-19 vaccine, nearly...

AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential. AstraZeneca is working to position itself...

Big pharma’s pivot to rare diseases continues as AstraZeneca (AZN) acquires Alexion Pharmaceuticals (ALXN) in a deal worth $39B.Subject to shareholder approval and certain regulatory clearances, the companies expect the deal to close in Q3 2021.The combined company is set to generate ~...

On Saturday morning, AstraZeneca (NASDAQ: AZN) announced an agreement to buy Alexion Pharmaceuticals (NASDAQ: ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. Based on AstraZeneca's closing price on Friday, Alexion shareh...

Alexion (ALXN) owners will receive $60 per share in cash and 2.1243 ADS of AstraZeneca (AZN) for each share of Alexion they own. Based on AZN's recent closing price, that implies a deal value of $39B, or $175 per share. That's about a 45% premium to Alexion's close on Friday.Al...

Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverage across prim...

The recent FDA approval of Orladeyo (Berotralstat) has completely de-risked BioCryst's future. Orladeyo has the ability to be a "blockbuster drug" and we are of the opinion that it very much has the ability to become Standard of Care. Income and a move to being FCF positive possib...